Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Poitiers University Hospital
Updated on 19 February 2024
cancer
squamous cell carcinoma
chemoradiotherapy
cancer treatment
carcinoma
obstructive sleep apnea syndrome
oropharyngeal
oropharyngeal cancer
oropharyngeal carcinoma
oropharyngeal squamous cell carcinoma

Summary

The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.

Details
Condition Oropharyngeal Cancer, Obstructive Sleep Apnea-hypopnea
Age 18-100 years
Clinical Study IdentifierNCT04440618
SponsorPoitiers University Hospital
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Age> 18 years old
Performance Status 0-2
Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy
Treatment termination time greater than 6 months at inclusion
Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3
Patient in complete remission at inclusion
patient's consent's obtained after information

Exclusion Criteria

Previous treatment for upper aerodigestive tract cancer
Incomplete radiotherapyTreatment
Neurological pathology wich may affect the functions of the upper aerodigestive tract
Pregnant or breastfeeding woman
Unweaned alcoholism
Tracheotomized patient at the time of the study
Patient under protection: subjects with guardianship or under law protection
No health insurance coverage
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.